INDP Indaptus Therapeutics, Inc.

Nasdaq indaptusrx.com


$ 3.73 $ 0.00 (0 %)    

Friday, 17-Oct-2025 04:25:40 EDT
QQQ $ 593.32 $ 0.00 (0 %)
DIA $ 456.36 $ 0.00 (0 %)
SPY $ 654.60 $ 0.00 (0 %)
TLT $ 91.46 $ 0.00 (0 %)
GLD $ 399.50 $ 0.00 (0 %)
$ 3.43
$ 3.76
$ 3.40 x 116
$ 4.28 x 1,500
-- - --
$ 2.22 - $ 58.24
158,983
na
3.8M
$ 1.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 indaptus-reports-partial-response-from-decoy20-monotherapy-in-urothelial-cancer-combo-with-pd-1-inhibitor-shows-favorable-safety

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION